1. 1 Long-term Testosterone Therapy Improves Erectile Function and Reduces Mortality in Men with Hypogonadism and Type 2 Diabetes – Updated Results from a Registry Study. Issue 1 (1st April 2022) Authors: Saad, F; Haider, A; Haider, KS; Doros, G; Traish, A Journal: Journal of sexual medicine Issue: Volume 19:Issue 1(2022)Supplement Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 6 Effects of Long-term Testosterone Therapy on Erectile Function in Obese Men with Functional Hypogonadism Receiving Long-term Testosterone Therapy- results From a Registry Study. Issue 1 (1st April 2022) Authors: Haider, A; Haider, KS; Doros, G; Traish, A; Saad, F Journal: Journal of sexual medicine Issue: Volume 19:Issue 1(2022)Supplement Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 804PHealth-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). (23rd October 2018) Authors: Small, E J; Cella, D; McQuarrie, K; Saad, F; Hadaschik, B A; Graff, J N; Uemura, H; Oudard, S; Yu, M K; Hudgens, S; Lopez-Gitlitz, A; Rooney, B; Morris, M; Smith, M R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 805PA phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region. (23rd October 2018) Authors: Fizazi, K; Hussain, M; Saad, F; Shore, N; De Giorgi, U; Efstathiou, E; Ferreira, U; Ivashchenko, P; Madziarska, K; Al-Adhami, M; Modelska, K; Phung, D; Steinberg, J; Sternberg, C N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 807PProlonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study. (23rd October 2018) Authors: Tombal, B; Hussain, M; Penson, D; Attard, G; Sternberg, C N; Phung, D; Morlock, R; Modelska, K; Ramaswamy, K; Ivanescu, C; Saad, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 824PRadium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (23rd October 2018) Authors: Miller, K; Heinrich, D; O'Sullivan, J M; Carles, J; Wirth, M; Nilsson, S; Huang, L; Kalinovsky, J; Heidenreich, A; Saad, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 826PUse of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE. (23rd October 2018) Authors: Sternberg, C N; Tombal, B; Miller, K; Saad, F; Sartor, O; Sade, J P; Logothetis, C; Bellmunt, J; Dizdarevic, S; Harshman, L C; Logue, J; Baldari, S; Richardson, T; Bottomley, D; Schostak, M; Bayh, I; Kalinovsky, J; Higano, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 827PClinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castration-resistant prostate cancer (mCRPC). (23rd October 2018) Authors: Higano, C S; Tombal, B; Miller, K; Saad, F; Sartor, O; Tangirala, K; Jiao, X; Kalinovsky, J; Sternberg, C N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 834PInterim results of a phase Ib study of niraparib plus androgen receptor-targeted therapy in men with metastatic castration-resistant prostate cancer. (23rd October 2018) Authors: Saad, F; Chi, K N; Shore, N; Graff, J N; Posadas, E M; Freeman, S; Tryon, J; Trudel, G C; de Jong, J; Meltzer, J; Zhao, X; Tran, N; Rezazadeh, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 859TiPTALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT). (23rd October 2018) Authors: de Bono, J S; Higano, C; Saad, F; Miller, K; Casey, M; Czibere, A; Healy, C; Fizazi, K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗